FOR: ONDINE BIOPHARMA CORPORATION
TSX, AIM SYMBOL: OBP
April 1, 2009
Ondine Expands MRSA Approvals With MRSAid(TM) Photodisinfection System
VANCOUVER, BRITISH COLUMBIA--(Marketwire - April 1, 2009) - Ondine Biopharma Corporation (TSX:OBP) (AIM:OBP) a
medical technology company developing photodisinfection-based products, today announced that it has received
additional Health Canada Licenses for its MRSAid(TM) Photodisinfection System. The system is designed to reduce
Methicillin-resistant Staphylococcus aureus (MRSA) colonization of the anterior nasal passages. The nose is a
major reservoir of this virulent pathogen and a primary route of transmission for hospital acquired infections.
"MRSA infections can be life-threatening events, placing huge burdens on our healthcare system," said Carolyn
Cross, Ondine's Chairman & CEO. "Approximately 94,000 life-threatening infections associated with MRSA are
reported annually in the US, resulting in more deaths each year than HIV/AIDS. Because these infections do not
respond to first-line antibiotic therapy, treatment is often complex, expensive and ineffective. Ondine's non-
antibiotic MRSAid(TM) system is designed to block carriage of these resistant microbes before transmission can
occur between patients, visitors and healthcare workers. The commercialization plan for the MRSAid(TM) system
includes continued in-hospital evaluations on high-level MRSA carriers, development of the US regulatory
pathway and establishment of distribution partners."
About Ondine Biopharma Corporation
Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and
viral infections. The Company is focused on developing leading edge products utilizing its patented light-
activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the
formation and spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada,
with a research and development laboratory in Bothell, Washington, USA, and an international office in St.
Michael, Barbados. For additional information, please visit the Company's website at: www.ondinebiopharma.com.
Forward-Looking Statements:
Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and
other similar expressions, are forward-looking statements that involve a number of risks and uncertainties.
Factors that could cause actual results to differ materially from those projected in the Company's forward-
looking statements include the following: market acceptance of our technologies and products; our ability to
obtain financing; our financial and technical resources relative to those of our competitors; our ability to
keep up with rapid technological change; government regulation of our technologies; our ability to enforce our
intellectual property rights and protect our proprietary technologies; the ability to obtain and develop
partnership opportunities; the timing of commercial product launches; the ability to achieve key technical
milestones in key products and other risk factors identified from time to time in the Company's public filings.
-30-
FOR FURTHER INFORMATION PLEASE CONTACT:
Ondine Biopharma Corporation
Carolyn Cross
Chairman and Chief Executive Officer
(604) 669-0555
Email: ccross@ondinebiopharma.com
Website: www.ondinebiopharma.com
OR
Canaccord Adams Ltd.
Ryan Gaffney
+4420 7050 6500
The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this
release.
INDUSTRY: Pharmaceuticals and Biotech-Biotech
SUBJECT: PDT
-0-
Ondine Biopharma Corporation